The long-term objective of the FORMAMP project is to significantly change the treatment strategies for infectious diseases and to reduce the evolution of multi-resistant bacteria
Start date: 2013-12-01
End date: 2017-11-31
Total Budget: 10.5 MEuro (EU contribution: 8 MEuro)
The project aims to develop new and innovative formulation strategies, based on the combination of nanotechnology-based delivery systems and antimicrobial peptides (AMPs), for the treatment of infectious diseases caused by bacteria such as P. aeruginosa (Pseudomonas aeruginosa), MRSA (Methicillin-resistant Staphylococcus aureus), and MTB (Mycobacterium tuberculosis).
– to evaluate and further develop a number of well-characterized nanostructured materials with excellent properties for peptide delivery applications.
– to develop functional prototype formulations based on the most promising nanostructured materials for AMP delivery that can be used to treat specific infections at their site of action.
Clinical indications that will be addressed include skin and soft tissue infections, infections in burn wounds, and infections in the lung such as cystic fibrosis and tuberculosis. A number of these indications are associated with the formation of multispecies biofilms, drastically impairing the function of available treatments. An important objective of the FORMAMP project is therefore to develop treatment strategies that also takes into account the problems associated with biofilms for clinical indications were this is of importance.